Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Genetic Screens02:46

Genetic Screens

5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gendered and nongendered language in genetic counseling.

Journal of genetic counseling·2026
Same author

Pay It Forward: Analysis of a novel peer-to-peer support initiative for individuals receiving treatment for head and neck cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Barriers and Facilitators to COVID-19 Vaccine Rollout among Health Professional Students: A Qualitative Study from an Organizational Stakeholder Perspective.

Disaster medicine and public health preparedness·2026
Same author

Is Preoperative Antimicrobial Prophylaxis Necessary in Testicular Torsion Surgery? Results from the National Surgical Quality Improvement Program Pediatric.

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie·2026
Same author

Ethics and Social Medicine Education Under Political Pressure: Teaching Through Uncertainty.

JAMA·2025
Same author

Programmable material via thiol-ene polymerization initiated by electric-field induced thiyl radical on piezoelectric ZnO.

Nature communications·2025

Related Experiment Video

Updated: Feb 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Direct-to-Consumer Genetic Testing and Orphan Drug Development.

Matthew Mason1, James Levenson1, John Quillin1

  • 1Virginia Commonwealth University School of Medicine , Richmond, Virginia.

Genetic Testing and Molecular Biomarkers
|July 12, 2017
PubMed
Summary

Partnerships between pharmaceutical companies and direct-to-consumer genetic testing companies are accelerating orphan drug development. These collaborations offer significant potential but also raise concerns regarding consumer privacy and healthcare costs.

Keywords:
direct-to-consumer genetic testingorphan drugspharmaceutical development

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

Related Experiment Videos

Last Updated: Feb 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

Area of Science:

  • Biotechnology
  • Genetics
  • Pharmacology

Background:

  • The Orphan Drug Act (ODA) of 1983 has significantly increased orphan drug approvals.
  • Financial incentives from the ODA are a primary driver of this growth.
  • Emerging partnerships between pharmaceutical firms and direct-to-consumer (DTC) genetic testing companies represent a new frontier.

Purpose of the Study:

  • To examine the regulatory landscape of rare-disease drugs.
  • To explore the increasing interest in nonclinical genetic testing.
  • To analyze the impact of DTC genetic testing companies on pharmaceutical research and development.

Main Methods:

  • Review of the Orphan Drug Act and its impact.
  • Analysis of DTC genetic testing company methodologies.
  • Overview of current DTC-pharma partnerships.
  • Examination of privacy and cost concerns associated with these collaborations.

Main Results:

  • Orphan drug approvals have risen dramatically since the ODA's inception.
  • DTC genetic testing offers valuable data for researchers and drug developers.
  • Existing partnerships demonstrate the synergistic potential of DTC-pharma collaborations.
  • Significant concerns regarding consumer privacy and healthcare system costs have been identified.

Conclusions:

  • DTC-pharma relationships hold immense potential for advancing rare-disease treatments.
  • These partnerships present considerable risks to consumer privacy.
  • The cost implications for the healthcare system require careful consideration and management.